Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis
Primary Purpose
Bleeding, Peptic Ulcer, Arterial Embolization
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
TAE
No TAE
Sponsored by
About this trial
This is an interventional treatment trial for Bleeding focused on measuring Bleeding peptic ulcer, Active bleeding, Trans-arterial angiographic embolization
Eligibility Criteria
Inclusion Criteria:
- Actively bleeding peptic ulcers (Forrest I), NBVV or Forrest IIa ulcer,
- Successful endoscopic hemostasis by combination treatment of injected epinephrine followed by either 3.2mm heat probe 30J (4 continuous pulses) or hemo-clipping (at least 2 clips) And one of the followings
- Spurting hemorrhage during endoscopy;
- Ulcer >= 2 cm is determined by an opened biopsy forceps;
- Hb on admission of < 9 g/dl; or
- Hypotension prior to endoscopy defined by SBP of <90 mmHg AND HR of >110 bmp
Exclusion Criteria:
-
Sites / Locations
- Endoscopy Centre, Prince of Wales Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
TAE group
No TAE group
Arm Description
Patients will be undergone TAE after endoscopic hemostasis.
No TAE procedure will be performed after endoscopic treatment.
Outcomes
Primary Outcome Measures
clinical re-bleeding
Clinical rebleeding is defined by fresh hematemesis, fresh melena or hematochezia and signs of hypovolemic shock (systolic blood pressure of <90mmHg and pulse rate >110 per minute) and a drop in hemoglobin of > 2 g/dl per 24 hours despite adequate transfusion.
Rebleeding will be confirmed by an immediate endoscopy showing fresh blood in stomach or active bleeding from a previously seen ulcer. A clinical rebleeding will be independently reviewed by an adjudication panel.
Secondary Outcome Measures
death from all causes
death from all causes
transfusion requirement
transfusion requirement
hospital stay including Intensive Care Unit stay
hospital stay including Intensive Care Unit stay
further interventions either further TAE or surgery
further interventions either further TAE or surgery
hospital costs
hospital costs
Full Information
NCT ID
NCT01142180
First Posted
June 9, 2010
Last Updated
July 17, 2018
Sponsor
Chinese University of Hong Kong
Collaborators
King Chulalongkorn Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01142180
Brief Title
Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis
Official Title
Early Selective Angiographic Embolization to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis - a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
January 2010 (Actual)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
Collaborators
King Chulalongkorn Memorial Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to determine if early angiographic embolization can forestall recurrent bleeding in selected high risk ulcers after their initial endoscopic control; to validate prospectively the investigators proposed in selecting high risk ulcers for recurrent bleeding in spite of maximal endoscopic control and profound acid suppression using high dose intravenous infusion of proton pump inhibitor; to characterize the nature of bleeding arteries in severely bleeding peptic ulcers and determine the efficacy of angiographic embolization in the prevention of recurrent bleeding and to establish safety profile of angiographic embolization as an early elective treatment to bleeding peptic ulcers.
Detailed Description
Endoscopic therapy is now the treatment of choice in patients with actively bleeding peptic ulcers and ulcers with non-bleeding visible vessels. Following endoscopic control of bleeding, we showed that the use of a high dose intravenous infusion of proton pump inhibitor (PPI) for 72 hours further reduced rate of recurrent bleeding [Lau NEJM 2000]. Recurrent bleeding still occurs in 8 to 10 percent of patients who receive the above treatment regime. The associated mortality following a rebleed is 4-10 fold higher when compared to those without recurrent bleeding. In a logistic regression model involving 1144 patients after successful endoscopic thermocoagulation to their bleeding peptic ulcers, we demonstrated that several factors independently predicted recurrent bleeding. They included hypotension, hemoglobin <10g/dl, fresh blood in the stomach, ulcer size > 2cm and active bleeding during endoscopy [Wong Gut 2003]. When we applied this model in a cohort of 945 patients who underwent endoscopic control of bleeding to their ulcers and adjunctive use of high dose intravenous PPI, 275 belonged to the high risk group. Of them, rebleeding leading to surgery or death occurred in 46 patients (16.7%)[Chiu DDW 2007]. Endoscopic treatment to bleeding peptic ulcers has its own limit. In an ex vivo bleeding model using canine mesenteric arteries, endoscopic thermocoagulation could only consistently seal arteries up to 2 mm in size [Johnson Gastro 1987]. Trans-arterial angiography allows clinicians to study and characterize bleeding arteries underneath peptic ulcers. In ulcers that erode into major arteries such as the gastro-duodenal artery complex and branches from left gastric artery, angiography complements endoscopic therapy in the form of selective coiling of the bleeding artery. Trans-arterial angiographic coiling can provide definitive control of bleeding from larger arteries i.e. > 2 mm in size. In cohort studies, trans-arterial angiographic coiling has been shown to compare favorably to surgery, and is less invasive in the control of severe bleeding in peptic
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bleeding, Peptic Ulcer, Arterial Embolization
Keywords
Bleeding peptic ulcer, Active bleeding, Trans-arterial angiographic embolization
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
258 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TAE group
Arm Type
Active Comparator
Arm Description
Patients will be undergone TAE after endoscopic hemostasis.
Arm Title
No TAE group
Arm Type
Active Comparator
Arm Description
No TAE procedure will be performed after endoscopic treatment.
Intervention Type
Procedure
Intervention Name(s)
TAE
Other Intervention Name(s)
Transarterial embolization
Intervention Description
The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
Intervention Type
Procedure
Intervention Name(s)
No TAE
Intervention Description
No TAE procedure will be performed after endoscopic treatment
Primary Outcome Measure Information:
Title
clinical re-bleeding
Description
Clinical rebleeding is defined by fresh hematemesis, fresh melena or hematochezia and signs of hypovolemic shock (systolic blood pressure of <90mmHg and pulse rate >110 per minute) and a drop in hemoglobin of > 2 g/dl per 24 hours despite adequate transfusion.
Rebleeding will be confirmed by an immediate endoscopy showing fresh blood in stomach or active bleeding from a previously seen ulcer. A clinical rebleeding will be independently reviewed by an adjudication panel.
Time Frame
within 30 days of therapy
Secondary Outcome Measure Information:
Title
death from all causes
Description
death from all causes
Time Frame
within 30 days of therapy
Title
transfusion requirement
Description
transfusion requirement
Time Frame
within 30 days of therapy
Title
hospital stay including Intensive Care Unit stay
Description
hospital stay including Intensive Care Unit stay
Time Frame
within 30 days of therapy
Title
further interventions either further TAE or surgery
Description
further interventions either further TAE or surgery
Time Frame
within 30 days of therapy
Title
hospital costs
Description
hospital costs
Time Frame
within 30 days of therapy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Actively bleeding peptic ulcers (Forrest I), NBVV or Forrest IIa ulcer,
Successful endoscopic hemostasis by combination treatment of injected epinephrine followed by either 3.2mm heat probe 30J (4 continuous pulses) or hemo-clipping (at least 2 clips) And one of the followings
Spurting hemorrhage during endoscopy;
Ulcer >= 2 cm is determined by an opened biopsy forceps;
Hb on admission of < 9 g/dl; or
Hypotension prior to endoscopy defined by SBP of <90 mmHg AND HR of >110 bmp
Exclusion Criteria:
-
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Y LAU, MD
Organizational Affiliation
Chinese University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Endoscopy Centre, Prince of Wales Hospital
City
Hong Kong
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
29802172
Citation
Lau JYW, Pittayanon R, Wong KT, Pinjaroen N, Chiu PWY, Rerknimitr R, Holster IL, Kuipers EJ, Wu KC, Au KWL, Chan FKL, Sung JJY. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut. 2019 May;68(5):796-803. doi: 10.1136/gutjnl-2018-316074. Epub 2018 May 25.
Results Reference
derived
Learn more about this trial
Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis
We'll reach out to this number within 24 hrs